The MarketWatch News Department was not involved in the creation of this content. -- Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and ...
LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...
Marstacimab significantly reduced ABR by 93% vs on-demand treatment over 12 months. Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with ...
Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...
TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche received the decision from the European Commission confirming that Hemlibra ® (emicizumab) , a ...
Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...
Factor deficiency or inhibition. The possible causes of the isolated prolonged aPTT in this case include factor deficiencies and factor inhibitors. Prolongation of both the PT and aPTT suggests ...
People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback